{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028363","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.199787+00:00","generated_at":"2026-05-31T19:43:50.859535+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation","bullets":["Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.","At Takeda he oversaw phase-appropriate development from Phase 1 through validation.","Previously held leadership roles at Shire, including VP of Pharmaceutical Sciences.","He holds a Ph.D. in Pharmaceutical Sciences from the University of Houston.","Appointment effective July 15, 2024; will oversee CMC activities across pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028363","json":"https://secwatch.observer/filing/0001493152-24-028363.json","markdown":"https://secwatch.observer/filing/0001493152-24-028363.md","text":"https://secwatch.observer/filing/0001493152-24-028363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:43:50.859535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7518916398","claim":"Srini Tenjarla was appointed as Senior Vice President, CMC & Formulation at Serina Therapeutics, Inc..","evidence_excerpt":"On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, CMC & Formulation"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}